These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 22646163

  • 1. Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.
    Grancha S, Ortiz AM, Marañón C, Hampel K, Moret A, Zimmermann B, Jorquera JI, Aznar JA.
    Haemophilia; 2012 Nov; 18(6):982-9. PubMed ID: 22646163
    [Abstract] [Full Text] [Related]

  • 2. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
    Mannucci PM, Shi Q, Bonanad S, Klamroth R.
    Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII.
    Montalvão SA, Tucunduva AC, Siqueira LH, Sambo AL, Medina SS, Ozelo MC.
    Haemophilia; 2015 Jul; 21(4):e281-5. PubMed ID: 25929310
    [Abstract] [Full Text] [Related]

  • 5. Understanding FVIII/VWF complex--report from a symposium of XXIX WFH meeting 2010.
    Gringeri A, Ofosu FA, Grancha S, Oldenburg J, Ewing NP, Federici AB.
    Haemophilia; 2012 May; 18(3):469-75. PubMed ID: 21943193
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Purification of recombinant human B-domain-deleted factor VIII using anti-factor VIII monoclonal antibody selected by the surface plasmon resonance biosensor.
    Oh HK, Lee JM, Byun TH, Park SY, Kim YH.
    Biotechnol Prog; 2001 May; 17(6):1119-27. PubMed ID: 11735450
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Management of bleeding disorders: basic science.
    Ofosu FA, Santagostino E, Grancha S, Marco P.
    Haemophilia; 2012 May; 18 Suppl 2():8-14. PubMed ID: 22530574
    [Abstract] [Full Text] [Related]

  • 10. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
    Neufeld EJ, Sidonio RF, O'Day K, Runken MC, Meyer K, Spears J.
    J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
    [Abstract] [Full Text] [Related]

  • 11. Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors.
    Bravo MI, Da Rocha-Souto B, Grancha S, Jorquera JI.
    Haemophilia; 2014 Nov; 20(6):905-11. PubMed ID: 25156825
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S, Dasgupta S, André S, Navarrete AM, Kaveri SV, Bayry J, André MH, Chtourou S, Tellier Z, Lacroix-Desmazes S.
    Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
    [Abstract] [Full Text] [Related]

  • 14. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.
    Seth Chhabra E, Liu T, Kulman J, Patarroyo-White S, Yang B, Lu Q, Drager D, Moore N, Liu J, Holthaus AM, Sommer JM, Ismail A, Rabinovich D, Liu Z, van der Flier A, Goodman A, Furcht C, Tie M, Carlage T, Mauldin R, Dobrowsky TM, Liu Z, Mercury O, Zhu L, Mei B, Schellenberger V, Jiang H, Pierce GF, Salas J, Peters R.
    Blood; 2020 Apr 23; 135(17):1484-1496. PubMed ID: 32078672
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB, van Velzen AS, Peyron I, Ten Brinke A, Fijnvandraat K, Voorberg J.
    Blood Rev; 2017 Sep 23; 31(5):339-347. PubMed ID: 28716211
    [Abstract] [Full Text] [Related]

  • 17. High-affinity von Willebrand factor binding does not affect the anatomical or hepatocellular distribution of factor VIII in rats.
    Øie CI, Roepstorff K, Behrens C, Bøggild Kristensen J, Karpf DM, Bolt G, Gudme CN, Kjalke M, Smedsrød B, Appa RS.
    J Thromb Haemost; 2016 Sep 23; 14(9):1803-13. PubMed ID: 27378673
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance.
    Santagostino E.
    Haemophilia; 2013 Jan 23; 19 Suppl 1():8-11. PubMed ID: 23278994
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.